skip to main content

NZM4

NZM4

Catalogue No.

17020205

Cell Line Name

NZM4

Cell Line Description

NZM4 is a cell line derived from a 56 year old male patient with metastatic malignant melanoma (peritoneal effusion)p53 mutant S241P(Ref: Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC. Radiation-induced cell cycle delays and p53 status of early passage melanoma lines. Oncol Res 2000; 12: 149-15)Wild-type for CDKN2A/B, PIK3CA, NRASTemozolomide resistant; MGMT expressed This cell line is distributed by ECACC on behalf of CellBank Australia, Children's Medical Research Institute, Westmead, NSW 2145, Australia. All stock supplied is manufactured and Quality Control released at source by CellBank Australia. CellBank Australia reference number: CBA-1390.

Characteristics

Tissue of Origin

Peritoneum (Ascites)

Morphology

Epithelial

Disease

Melanoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Remove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line. Medium Renewal: 2-3 times per week. Subcultivation ratio: 1:4-1:8, Seeding density 1.3 x10⁴ cells/cm². Split subconfluent cultures (70-80%). Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes. Culture conditions: Incubate the culture at 37°C with 5% CO₂. Cryoprotectant Medium: 10% DMSO + 90% FCS

Culture Medium

This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS), 5 µg/ml Insulin, 5 µg/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5% O₂, 5% CO₂ and 90% N₂. At CellBank Australia it has been cultured in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS), 5µg/ml Insulin, 5µg/ml Transferrin, 5ng/ml Sodium Selenite (ITS), in an atmosphere of 5% CO₂.

Growth Mode

Adherent and floating viable cells

Additional Info

Depositor

Professor Bruce Baguley - The University of Auckland

Country of Origin

New Zealand

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Marshall ES, Matthews JHL, Shaw JHF, Nixon J, Tumewu P, Finlay GJ, Holdaway KM, Baguley BC. Radiosensitivity testing of human melanoma cell lines: comparison of [3H]-thymidine incorporation and soft agar clonogenic assays. Eur J Cancer 1994; 30A: 1370-1376 PMID: 7999427

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: NZM4 (ECACC 17020205).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.